Tag: options

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Provident Bancorp, Inc. (NASDAQ: PVBC) to NB Bancorp, Inc. is fair to Provident shareholders. Under the terms of the proposed transaction, Provident shareholders will receive for each share of Provident common stock, at the holder’s election, either (i) 0.691 shares of NB Bancorp common stock or (ii) $13.00 in cash.

Investors can contact the law firm at no cost to learn more about recovering their losses​

URGN Investors with Losses Encouraged to Contact Hagens Berman

RoboCat Reinvents Itself with a New Brand Identity to Capture Canada’s New Online Casinos Audience by Introducing Bigger Bonuses and New Games

Uptown Aces Casino is introducing a fun-filled experience to ramp up the excitement with its latest offering: 100 free spins with no deposit.

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025.

Company Introduces 100% Natural Gummy Supplements Including Mushroom, Collagen, and Turmeric Formulations

CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company’s umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain.

With sincere enthusiasm and unwavering devotion to providing rewarding, innovative, and truly thrilling memories, SlotoCash is excited to unveil a broader collection of real-money online slots.